Success Metrics

Clinical Success Rate
88.5%

Based on 23 completed trials

Completion Rate
88%(23/26)
Active Trials
16(33%)
Results Posted
48%(11 trials)
Terminated
3(6%)

Phase Distribution

Ph phase_1
12
24%
Ph not_applicable
6
12%
Ph early_phase_1
3
6%
Ph phase_4
1
2%
Ph phase_2
12
24%
Ph phase_3
2
4%

Phase Distribution

15

Early Stage

12

Mid Stage

3

Late Stage

Phase Distribution36 total trials
Early Phase 1First-in-human
3(8.3%)
Phase 1Safety & dosage
12(33.3%)
Phase 2Efficacy & side effects
12(33.3%)
Phase 3Large-scale testing
2(5.6%)
Phase 4Post-market surveillance
1(2.8%)
N/ANon-phased studies
6(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.2%

23 of 27 finished

Non-Completion Rate

14.8%

4 ended early

Currently Active

16

trials recruiting

Total Trials

49

all time

Status Distribution
Active(19)
Completed(23)
Terminated(4)
Other(3)

Detailed Status

Completed23
Recruiting13
Terminated3
Active, not recruiting3
unknown3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
49
Active
16
Success Rate
88.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (8.3%)
Phase 112 (33.3%)
Phase 212 (33.3%)
Phase 32 (5.6%)
Phase 41 (2.8%)
N/A6 (16.7%)

Trials by Status

terminated36%
recruiting1327%
completed2347%
enrolling_by_invitation12%
not_yet_recruiting24%
active_not_recruiting36%
unknown36%
withdrawn12%

Recent Activity

Clinical Trials (49)

Showing 20 of 49 trialsScroll for more
NCT07217028Phase 1

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Not Yet Recruiting
NCT04895631Phase 3

18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

Completed
NCT05388006Phase 2

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
NCT05888532Phase 1

64Cu-GRIP B in Patients With Advanced Malignancies

Recruiting
NCT07078604Phase 2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Recruiting
NCT04044937Phase 2

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

Completed
NCT06675357Phase 2

Using FAPI PET/MRI to Evaluate Prostate Cancer

Recruiting
NCT06470282Phase 1

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Recruiting
NCT06821646

Investigating the Brain's Physiological Responses in Depression and Autism, Using Transcranial Magnetic Stimulation and Electroencephalography

Enrolling By Invitation
NCT06522932Phase 1

PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

Recruiting
NCT02904187Not Applicable

Cerebral Activation and Bilateral Stimulation by Cochlear Implantation in Bilateral Deaf Adults

Completed
NCT06862856

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

Recruiting
NCT07218224

Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas

Unknown
NCT07087210

In Vivo Quantitative Mapping of Mitochondrial Cardiac Membrane Potential in Heart Failure

Active Not Recruiting
NCT05059158

Amyloid-β Clearance Mechanisms in Alzheimer's Disease

Recruiting
NCT01937117Phase 2

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Active Not Recruiting
NCT00873275Phase 1

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Completed
NCT06600880Phase 1

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

Not Yet Recruiting
NCT05614310

Detecting Early Alzheimer's Using MR

Recruiting
NCT05180162Phase 1

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
49